La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AC Immune Gestione

Gestione criteri di controllo 3/4

AC Immune's Il CEO è Andrea Pfeifer, nominato in Apr2003, e ha un mandato di 21.33 anni. la retribuzione annua totale è CHF 2.65M, composta da 21.8% di stipendio e 78.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.45% delle azioni della società, per un valore di $ 8.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 6.3 anni.

Informazioni chiave

Andrea Pfeifer

Amministratore delegato

CHF 2.7m

Compenso totale

Percentuale dello stipendio del CEO	21.8%
Mandato del CEO	21.3yrs
Proprietà del CEO	2.4%
Durata media del management	3.9yrs
Durata media del Consiglio di amministrazione	6.3yrs

Aggiornamenti recenti sulla gestione

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Andrea Pfeifer rispetto agli utili di AC Immune?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CHF 61m
Mar 31 2024	n/a	n/a	-CHF 55m
Dec 31 2023	CHF 3m	CHF 578k	-CHF 54m
Sep 30 2023	n/a	n/a	-CHF 68m
Jun 30 2023	n/a	n/a	-CHF 67m
Mar 31 2023	n/a	n/a	-CHF 69m
Dec 31 2022	CHF 2m	CHF 558k	-CHF 71m
Sep 30 2022	n/a	n/a	-CHF 73m
Jun 30 2022	n/a	n/a	-CHF 76m
Mar 31 2022	n/a	n/a	-CHF 75m
Dec 31 2021	CHF 2m	CHF 530k	-CHF 73m
Sep 30 2021	n/a	n/a	-CHF 71m
Jun 30 2021	n/a	n/a	-CHF 74m
Mar 31 2021	n/a	n/a	-CHF 71m
Dec 31 2020	CHF 2m	CHF 520k	-CHF 62m
Sep 30 2020	n/a	n/a	-CHF 62m
Jun 30 2020	n/a	n/a	-CHF 25m
Mar 31 2020	n/a	n/a	-CHF 26m
Dec 31 2019	CHF 2m	CHF 510k	CHF 45m
Sep 30 2019	n/a	n/a	CHF 50m
Jun 30 2019	n/a	n/a	CHF 18m
Mar 31 2019	n/a	n/a	CHF 24m
Dec 31 2018	CHF 2m	CHF 455k	-CHF 51m
Sep 30 2018	n/a	n/a	-CHF 32m
Jun 30 2018	n/a	n/a	-CHF 27m
Mar 31 2018	n/a	n/a	-CHF 29m
Dec 31 2017	CHF 2m	CHF 404k	-CHF 26m

Compensazione vs Mercato: La retribuzione totale di Andrea ($USD 3.07M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Andrea è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Andrea Pfeifer (67 yo)

21.3yrs

Mandato

CHF 2,650,000

Compensazione

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrea Pfeifer	Co-Founder	21.3yrs	CHF 2.65m	2.45% CHF 8.3m
Christopher Roberts	CFO & VP of Finance	2.3yrs	Nessun dato	0.013% CHF 43.0k
Piergiorgio Donati	Chief Technical Operations Officer	5.5yrs	Nessun dato	0.025% CHF 83.6k
Jean-Fabien Monin	Chief Administrative Officer	9.1yrs	Nessun dato	0.32% CHF 1.1m
Howard Donovan	Chief HR Officer	2.3yrs	Nessun dato	0.020% CHF 68.7k
Nuno Mendonca	Chief Medical Officer	less than a year	Nessun dato	0.0083% CHF 28.0k
Madiha Derouazi	Chief Scientific Officer	less than a year	Nessun dato	0.0032% CHF 10.8k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Alexandre Caratsch	General Counsel	no data	Nessun dato	Nessun dato
Julian Snow	VP of U.S. Finance & Corporate Development	2.3yrs	Nessun dato	Nessun dato
David Hickman	Head of AD - SME	14.6yrs	Nessun dato	Nessun dato
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.5yrs	Nessun dato	Nessun dato

3.9yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di ACIU è considerato esperto (durata media dell'incarico 3.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrea Pfeifer	Co-Founder	8.3yrs	CHF 2.65m	2.45% CHF 8.3m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Claude Nicolau	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Douglas Williams	Independent Non-Executive Chairman	6.3yrs	CHF 179.00k	0.039% CHF 132.8k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF 5.00k	Nessun dato
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF 105.00k	Nessun dato
I. Rosenberg	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
M. Monsigny	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
E. Lestringant	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Monika Butler	Independent Vice Chair	2.8yrs	CHF 163.00k	0.0092% CHF 31.2k
Andreas Monsch	Head of Clinical Advisory Board	no data	Nessun dato	Nessun dato

6.3yrs

Durata media

74.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ACIU sono considerati esperti (durata media dell'incarico 6.3 anni).

AC Immune Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA, Annual General Meeting, Jun 20, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Co-Founder notifies of intention to sell stock

Recent updates

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

New 90-day high: US$8.43